Nektar Therapeutics (NKTR) Cash & Current Investments (2010 - 2026)

Nektar Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $568.6 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 160.07% year-over-year to $568.6 million in Q1 2026; TTM through Mar 2026 was $568.6 million, a 160.07% increase from a year earlier, with the FY2025 full-year figure at $245.8 million, down 3.71% from the prior year.
• Cash & Current Investments climbed to $568.6 million in Q1 2026 per NKTR's latest filing, from $245.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $667.0 million in Q1 2022 and bottomed at $175.9 million in Q2 2025.
• The 5-year median for Cash & Current Investments is $303.6 million (2023), against an average of $377.6 million.
• Across the five-year window, Cash & Current Investments slumped 40.68% in 2022 and surged 160.07% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $505.0 million in 2022, then plunged by 39.88% to $303.6 million in 2023, then decreased by 15.94% to $255.2 million in 2024, then decreased by 3.71% to $245.8 million in 2025, then soared by 131.37% to $568.6 million in 2026.
• Per Business Quant, the three latest NKTR Cash & Current Investments figures stand at $568.6 million (Q1 2026), $245.8 million (Q4 2025), and $270.2 million (Q3 2025).